Sugi Predict

Sugi Predict / Compounds / SCHEMBL20003539

SCHEMBL20003539

SCHEMBL20003539

O=S(=O)(Cl)c1ccc(OC(F)F)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.46
▸ TRPV4 Q9HBA0 1/20 0.44
▸ DAO P14920 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ CHRNA7 P36544 1/20 0.36
▸ MLNR O43193 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ HDAC6 Q9UBN7 2/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ PABPC1 P11940 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ TRPA1 O75762 1/20 0.32
▸ KDM4E B2RXH2 2/20 0.31
▸ PTGDR Q13258 1/20 0.31
▸ HCRTR1 O43613 2/20 0.31
▸ HCRTR2 O43614 2/20 0.31
▸ FBP1 P09467 1/20 0.30
▸ GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29995133 0.83 ALDH1A1 (0.67) ALDH1A1HSD17B10TDP1CHRNA7MLNR
SCHEMBL307288 0.83 ALDH1A1 (0.67) ALDH1A1HSD17B10TDP1CHRNA7MLNR
Hydrochloric Acid SCHEMBL28296115 0.81 KDM4E (0.47) ALDH1A1TRPV4DAOHSD17B10CHRNA7
SCHEMBL28016001 0.77 CA1 (0.47) ALDH1A1HSD17B10TDP1MEN1PABPC1
SCHEMBL30269658 0.77 CA1 (0.47) ALDH1A1HSD17B10TDP1MEN1PABPC1
SCHEMBL119737 0.77 CA1 (0.47) ALDH1A1HSD17B10TDP1MEN1PABPC1
SCHEMBL29087331 0.76 ALDH1A1 (0.36) ALDH1A1HSD17B10TDP1HDAC6MEN1
SCHEMBL856562 0.76 TRPV4 (0.46) ALDH1A1TRPV4HSD17B10TDP1SMN1; SMN2
SCHEMBL21144508 0.73 ALDH1A1 (0.40) ALDH1A1TRPV4HSD17B10TDP1CHRNA7
SCHEMBL26131622 0.72 HSPB1 (0.56) ALDH1A1MLNRCYP2D6MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159538-A1 PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS, INC. 2023-05-25 — — US disclosed
US-20230159538-A1 PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS, INC. 2023-05-25 — — US disclosed
EP-4126876-A1 PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS Global Blood Therapeutics, Inc. (US) 2023-02-08 — — EP disclosed
CN-109952289-B TRPV4 antagonists 葛兰素史密斯克莱知识产权（第2 号）有限公司 2022-12-09 — — CN disclosed
CN-109790116-B TRPV4 antagonists 葛兰素史密斯克莱知识产权（第2 号）有限公司 2022-10-28 — — CN disclosed
US-11260049-B2 TRPV4 antagonists GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2022-03-01 — — US disclosed
US-11229623-B2 TRPV4 antagonists GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2022-01-25 — — US disclosed
US-11229623-B2 TRPV4 antagonists GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2022-01-25 — — US disclosed
WO-2021202796-A1 PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-10-07 — — WO disclosed
US-20210299113-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2021-09-30 — — US disclosed
EP-3515888-A1 TRPV4 ANTAGONISTS GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) 2019-07-31 — — EP disclosed
EP-3515887-A1 TRPV4 ANTAGONISTS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2019-07-31 — — EP disclosed
US-20190216774-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-07-18 — — US disclosed
US-20190216774-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-07-18 — — US disclosed
CN-109952289-A TRPV4 antagonist 葛兰素史密斯克莱知识产权（第2 号）有限公司 2019-06-28 — — CN disclosed
CN-109790116-A TRPV4 antagonist 葛兰素史密斯克莱知识产权（第2 号）有限公司 2019-05-21 — — CN disclosed
WO-2018055524-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-03-29 — — WO disclosed
WO-2018055524-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-03-29 — — WO disclosed
WO-2018055526-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-03-29 — — WO disclosed
WO-2018055526-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-03-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11260049-B2 TRPV4 antagonists TRPV4, TRPV5, TRPV2 ALDH1A1 3265/4885TRPV4 1/4885DAO 4450/4885
US-20210299113-A1 TRPV4 ANTAGONISTS TRPV4, TRPV5, TRPV2 ALDH1A1 3265/4885TRPV4 1/4885DAO 4450/4885
US-11229623-B2 TRPV4 antagonists TRPV4, TRPV5, TRPV2 ALDH1A1 3265/4885TRPV4 1/4885DAO 4450/4885
US-20190216774-A1 TRPV4 ANTAGONISTS TRPV4, TRPV5, TRPV2 ALDH1A1 3265/4885TRPV4 1/4885DAO 4450/4885
US-20230159538-A1 PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS PDK1, PDK2, PKM ALDH1A1 1784/4885TRPV4 2312/4885DAO 3754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.